Oxford Biomedica PLC — Investor Relations & Filings
Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. A pioneer in the field, the company has extensive experience in viral vectors, the enabling technology for many advanced therapies. OXB provides end-to-end services to pharmaceutical and biotechnology partners, supporting programs from preclinical development through to commercial launch. Its core expertise includes the development and GMP manufacturing of various vector types, including lentivirus, adeno-associated virus (AAV), and adenovirus. The company offers proprietary technologies like its LentiVector™ platform, the first commercially approved lentiviral system, and its inAAVate™ platform for AAV, in addition to tech-transfer capabilities.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Total Voting Rights | 2026-05-01 | English | |
| Admission to Trading | 2026-04-30 | English | |
| Admission to Trading Application | 2026-04-27 | English | |
| Launch of viral vector fast-track offering | 2026-04-13 | English | |
| Grant of Awards | 2026-04-08 | English | |
| Total Voting Rights | 2026-04-01 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 39399113 | Total Voting Rights | 2026-05-01 | English | ||
| 39034920 | Admission to Trading | 2026-04-30 | English | ||
| 37376856 | Admission to Trading Application | 2026-04-27 | English | ||
| 34392469 | Launch of viral vector fast-track offering | 2026-04-13 | English | ||
| 33897356 | Grant of Awards | 2026-04-08 | English | ||
| 33128279 | Total Voting Rights | 2026-04-01 | English | ||
| 33090029 | Annual financial and audit reports | 2026-03-30 | English | ||
| 33090024 | Annual financial and audit reports | 2026-03-30 | English | ||
| 33090019 | 2026 Annual General Meeting notification | 2026-03-30 | English | ||
| 33089974 | 2026 Notice of AGM | 2026-03-30 | English | ||
| 33045671 | Preliminary results for the year ended 31 Dec 2025 | 2026-03-26 | English | ||
| 32970907 | Licensing agreement with VVMF | 2026-03-18 | English | ||
| 32916724 | Admission to Trading | 2026-03-09 | English | ||
| 32882398 | Admission to Trading Application | 2026-03-04 | English | ||
| 32869317 | Capital Markets Day and investor conferences | 2026-03-03 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for Oxford Biomedica PLC, but not for this combination of statement and period. Try a different combination.
| Line item | ! |
|---|---|
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
|
Adaptimmune Therapeutics PLC
Commercial-stage biopharma developing TCR T-cell therapies …
|
ADAP | GB | Manufacturing |
Oxford Biomedica PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/5190/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=5190 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=5190 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=5190 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 5190}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Oxford Biomedica PLC (id: 5190)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.